New therapies and gene target advance the treatment and understanding of hard-to-treat... (induction chemotherapy alone does not pr...)

New therapies and gene target advance the treatment and understanding of hard-to-treat leukemias

Date:12/6/2010

induction chemotherapy alone does not produce prolonged remissions. Therefore, an allogeneic stem cell transplant, in which a patient receives stem cells from a sibling or unrelated matched donor, is often recommended after the first complete remission.

In 1993 researchers from the National Cancer Research Institute in the United Kingdom and the Eastern Cooperative Oncology Group in the United States initiated a study to evaluate whether allogeneic stem cell transplant is an effective treatment option for adult patients with Ph+ ALL. In this study, 266 patients received two phases of induction chemotherapy followed by an allogeneic stem cell transplant ("pre-imatinib" arm). Following the availability of imatinib, a targeted BCR-ABL inhibitor, the purpose of the study was modified in 2003 to include and evaluate the use of imatinib as part of consolidation therapy prior to an allogeneic stem cell transplant ("late-imatinib" arm) or as part of standard induction therapy prior to the transplant ("early-imatinib" arm). Results from the pre-imatinib cohort (Fielding, Blood 2009) were then used as a benchmark for use of imatinib in patients with Ph+ ALL.

In the late-imatinib arm of the study, 86 patients received imatinib 600 mg a day as part of consolidation therapy prior to undergoing an allogeneic stem cell transplant following two induction chemotherapy regimens. Those in the early-imatinib arm (89 patients) were given imatinib 600 mg earlier as part of the second chemotherapy induction phase prior to the allogeneic stem cell transplant. All patients who received an allogeneic stem cell transplant in the study were given imatinib for two years post-transplant. If a transplant was not feasible for any reason, imatinib could be given as a maintenance therapy for two years.

Results from this study, the largest international study of patients with Ph+ ALL evaluating allogeneic stem cell transplantation (control group) and the use of im
'/>"/>

Contact: Lindsey Love
llove@hematology.org
540-538-9326
American Society of Hematology
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. MSU researcher linking breast cancer patients with alternative therapies
2. Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
3. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
4. NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT)
5. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
6. Intense Cholesterol, Blood Pressure Therapies Dont Help Type 2 Diabetics
7. Study evaluates costs and benefits associated with new colon cancer therapies
8. New therapies increase survival rates in post-transplant liver cancer patients
9. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
10. Molecular discovery points to new therapies for brain tumors
11. Ovarian cancer study offers vital clues for new therapies

Post Your Comments:

(Date:6/19/2013)... PrettySkin4Less announces it is stocking up with ... top skin care manufacturer EMINENCE to meet customer demands. ... and active organic ingredients to promote actual change rather ... products offer. For this reason it’s not hard to ... like products that do what they say they will ...

(Date:6/19/2013)... Lake City, UT (PRWEB) June 19, 2013 ... companies : , In July 2013, Orriant is ... their participation rates, and maintain compliance with regulations. ... allowing employees to receive wellness incentives if their ... has announced they have been compliant with these ...

(Date:6/19/2013)... June 19, 2013 As Januvia ... continue to mount in courts throughout the U.S., Bernstein ... Administration (FDA) recently held a meeting to discuss the ... incretin mimetics. According to a June 12th report ... the makers of Januvia and similar drugs, following a ...

(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...

(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...

Breaking Medicine News(10 mins):Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2 Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2 Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3 Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2 Health News:States vary widely on success rates for minorities in drug treatment programs 2 Health News:States vary widely on success rates for minorities in drug treatment programs 3

[0] PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base [0] New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations [0] Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics [0] Long-term study reports deep brain stimulation effective for most common hereditary dystonia [0] States vary widely on success rates for minorities in drug treatment programs

... , NORTH DARTMOUTH, Mass., Sept. 10 The ... is now offering all sleep medicine services at one location. ... the 84 Faunce Corner Road location in North Dartmouth, MA, ... their sleep disorders. , , While at ...

... , BALTIMORE, Sept. 10 The following statement ... Addiction Treatment Gap (CATG) initiative: , , ... addiction remains at pandemic levels, with 23 million Americans suffering from ... diabetes. But you wouldn,t know it from the way our ...

... , FORT LAUDERDALE, Fla., Sept. 10 ... on the dangers of synthetic hormone replacement therapy for menopausal women, ... safer treatment option. , , A white ... , published in the October edition of Life Extension ...

... NEW YORK, Sept. 10 Reportlinker.com announces that a new ... , North America Air Purification Equipment ... http://www.reportlinker.com/p0109900/North-America-Air-Purification-Equipment-Market.html , , ... Equipment in US$ Million & Thousand Units The market is ...

... SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: ... of technology and pharmacy benefit management (PBM) services, announced ... to June 30, 2011, for its informedRx PBM business ... Hawaii. Under the agreement, SXC is providing full-service PBM ...

... Sept. 10 Reportlinker.com announces that a new market research ... World Botulinum Toxin Market , ... This report analyzes the worldwide markets for Botulinum ... for ,Botulinum Toxin, by the Following Segments: Cosmetic, and Therapeutic ...

Sleep HealthCenters and Southcoast Hospitals Group Expand Patient Services in North Dartmouth Closing the Addiction Treatment Gap (CATG) Statement on Annual National Survey on Drug Use and Health Data Released by the Substance Abuse and Mental Health Services Administration (SAMHSA)The End of the Bio-Identical Hormone Debate Reportlinker Adds North America Air Purification Equipment Market Report SXC Health Solutions announces PBM contract renewal with Hawaii Employer-Union Health Benefits Trust Fund Reportlinker Adds World Botulinum Toxin Market Report

(Date:6/19/2013)... YORK , June 19, 2013 /PRNewswire-iReach/ -- ... pioneer of modern hair transplant procedures and founder ... was included in the ,Best Doctors, issue of ... (Photo: http://photos.prnewswire.com/prnh/20130619/CG34629 ) ... Best Doctors issue, and his reputation as world-renowned ...

(Date:6/19/2013)... PHILADELPHIA , June 19, 2013 Echo ... company developing its needle-free Symphony ® CGM ... system, today announced the closing of a previously ... its common stock and the full exercise of ... offered at a price to the public of ...

(Date:6/19/2013)... INDIANAPOLIS , June 19, 2013 Eli ... issued an alert about two illegal scams, purportedly using ... Animal Health, that are actively targeting the public through ... and Elanco have no connection to any foreign lottery ... recruiting described by the job-seeking victims of the scam. ...

Breaking Medicine Technology:Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2 Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3 Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter 2 Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter 3 Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests 2

[0] Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year [0] Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter [0] Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests

... 16, 2011 A group of 22 bipartisan House Members ... Services (CMS) asking the agency to stop their prepayment ... for Medicare beneficiaries. The lawmakers, who included ... cited potential job losses, restricted access to mobility equipment ...

... N.Y., Dec. 16, 2011 At a morning ceremony ... , along with administrators and faculty members of ... celebrated the re-launch of Einstein,s Gruss Magnetic Resonance ... support, Einstein now houses an advanced magnetic resonance imaging ...

Cached Medicine Technology:Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries 2 Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries 3 NYC Council Member James Vacca Helps Brings Advanced MRI Technology to Einstein College of Medicine 2 NYC Council Member James Vacca Helps Brings Advanced MRI Technology to Einstein College of Medicine 3

Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries NYC Council Member James Vacca Helps Brings Advanced MRI Technology to Einstein College of Medicine

... Our thawing systems are automated, easy to ... from the outside environment by flexible snap-seal ... bacterial or viral contamination of the water. ... the systems can also accommodate bags of ...

... thawing systems are automated, easy to operate ... the outside environment by flexible snap-seal pockets ... or viral contamination of the water. Offered ... systems can also accommodate bags of various ...

Conventional Digitally-Controlled Water Baths...

Dry thaws. Has an ingenious (pat. pending) massaging sytem that utilizes the tempered bladders as hands. There are no unreliable mechanical parts involved. Two pumps pressurize different segments of ...

Medicine Products:

Thermoline™ Blood Component Thawing System MT-210 Thermoline™ Blood Component Thawing System MT-202 CytoTherm-4T CytoTherm-D4